<DOC>
	<DOCNO>NCT00400348</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , limited pharmacokinetics ( PK ) , safety 1,000 mg Panzem® NCD administer orally four time day patient recurrent resistant epithelial ovarian cancer .</brief_summary>
	<brief_title>Safety Efficacy Study Panzem® Nanocrystal Colloidal Dispersion Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>2-methoxyestradiol</mesh_term>
	<criteria>1 . Written inform consent HIPAA authorization release protect health information . 2 . Have histologicallyconfirmed : epithelial ovarian cancer primary peritoneal carcinomatosis fallopian tube cancer . Enrollment patient clear cell histology encourage . 3 . Have measurable disease accord RECIST detectable disease 1 ) CA125 least twice ULN within 14 day prior registration protocol therapy ; 2 ) Ascites and/or pleural effusion attribute tumor ; 3 ) solid and/or cystic abnormality radiographic image meet RECIST definition target lesion . Radiographic assessment must obtain within 28 day prior registration protocol therapy . 4 . Be 18 year age old time consent . 5 . Be least 4 week since last anticancer treatment , radiation surgery time registration protocol therapy ( exception hormonal therapy , 1 week washout period sufficient ; minor surgery , catheter placement removal within 1 week enrollment allow ) . 6 . Have fail least one prior platinum base chemotherapeutic regimen . ( Platinum failure define Platinumrefractory ( progression receive platinumcontaining regimen ) platinumresistant ( disease progression within 6 month completion platinumcontaining regimen ) . 7 . Have life expectancy least 3 month . 8 . Have ECOG performance status 0 1 assess within 14 day prior registration protocol therapy . 9 . Have nearnormal organ function , evidence laboratory data within 14 day prior registration protocol therapy : Aspartate aminotransferase alanine aminotransferase less 2.5 time upper limit normal ( ULN ) Total bilirubin less 1.5 time ULN Alkaline phosphatase less 2.5 time ULN Absolute neutrophil count great equal 1,500 cells/mm3 White blood cell count great equal 3,000 cells/mm3 Hemoglobin great equal 9.0 g/dL Platelets great 75,000/mm3 Creatinine level less 1.5 time ULN 10 . Have evidence bowel obstruction , malabsorption , contraindication oral medication . 11 . Females childbearing potential must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) treatment . 12 . Females childbearing potential must negative pregnancy test within 7 day prior register protocol therapy . Subjects consider childbearing potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . 1 . Be breastfeed . 2 . Have condition likely interfere regular followup . 3 . Have history myocardial infarction angina pectoris angina equivalent within 6 month prior registration protocol therapy ( patient may antianginal medication symptom entirely control ) , uncontrolled hypertension congestive heart failure . 4 . Have participate clinical trial involve conventional investigational drug device within 4 week prior registration protocol therapy . 5 . Have active cancer addition epithelial ovarian cancer within last 5 year , exception : superficial skin cancer ( basal cell squamous cell skin carcinoma ) carcinoma situ cervix Stage I endometrial cancer le 50 % invasion myometrium , adequately treated Stage I II cancer complete remission . 6 . Have active infection require antibiotic treatment . 7 . Be receive concurrent anticoagulation therapy ( low dose coumadin portacath maintenance allow ) . 8 . Have additional uncontrolled serious medical condition psychiatric illness . 9 . Be receive combination antiretroviral therapy treatment immunodeficiency . 10 . Have brain metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>